Deborah Toppmeyer

9.8k total citations · 2 hit papers
94 papers, 3.4k citations indexed

About

Deborah Toppmeyer is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Deborah Toppmeyer has authored 94 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 32 papers in Cancer Research and 27 papers in Genetics. Recurrent topics in Deborah Toppmeyer's work include Breast Cancer Treatment Studies (28 papers), BRCA gene mutations in cancer (23 papers) and Cancer Treatment and Pharmacology (21 papers). Deborah Toppmeyer is often cited by papers focused on Breast Cancer Treatment Studies (28 papers), BRCA gene mutations in cancer (23 papers) and Cancer Treatment and Pharmacology (21 papers). Deborah Toppmeyer collaborates with scholars based in United States, Canada and Japan. Deborah Toppmeyer's co-authors include Bruce G. Haffty, Thomas Kearney, Qifeng Yang, Lyndsay N. Harris, Susan A. Higgins, Michael Reiß, Joanne B. Weidhaas, Eric P. Winer, Hope S. Rugo and Kim M. Hirshfield and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Deborah Toppmeyer

87 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

2006 874 citations Bruce G. Haffty, Deborah Toppmeyer et al. Journal of Clinical Oncology profile →
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Toppmeyer United States	26	2.3k	1.2k	1.1k	678	388	94	3.4k
Attila Tordai Hungary	29	2.0k 0.9×	1.7k 1.4×	1.6k 1.4×	519 0.8×	701 1.8×	121	4.6k
Jeremy Braybrooke United Kingdom	23	1.4k 0.6×	979 0.8×	1.0k 0.9×	674 1.0×	210 0.5×	64	2.9k
Laura Orlando Italy	27	1.9k 0.8×	1.3k 1.1×	946 0.9×	543 0.8×	341 0.9×	92	2.9k
Stéphanie Lheureux Canada	27	1.6k 0.7×	1.1k 0.9×	1.8k 1.6×	560 0.8×	414 1.1×	153	4.3k
Thaer Khoury United States	32	1.5k 0.7×	1.1k 0.9×	1.1k 1.0×	453 0.7×	675 1.7×	153	3.1k
Robert M. Wenham United States	33	1.4k 0.6×	1.4k 1.1×	2.3k 2.1×	483 0.7×	503 1.3×	158	4.7k
Thomas Hatschek Sweden	29	2.4k 1.1×	1.9k 1.5×	1.1k 1.0×	956 1.4×	480 1.2×	100	4.5k
Ann Knoop Denmark	27	1.8k 0.8×	1.3k 1.0×	912 0.8×	517 0.8×	215 0.6×	116	2.7k
Catriona M. McNeil Australia	31	3.2k 1.4×	874 0.7×	1.9k 1.8×	698 1.0×	297 0.8×	103	4.7k
Stacy L. Moulder United States	32	2.5k 1.1×	1.3k 1.0×	1.4k 1.3×	922 1.4×	419 1.1×	141	3.9k

Countries citing papers authored by Deborah Toppmeyer

Since Specialization

Citations

This map shows the geographic impact of Deborah Toppmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Toppmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Toppmeyer more than expected).

Fields of papers citing papers by Deborah Toppmeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Toppmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Toppmeyer. The network helps show where Deborah Toppmeyer may publish in the future.

Co-authorship network of co-authors of Deborah Toppmeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Toppmeyer. A scholar is included among the top collaborators of Deborah Toppmeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Toppmeyer. Deborah Toppmeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McDougall, Jean A., Yong Lin, Shou‐En Lu, et al.. (2024). Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up. JNCI Cancer Spectrum. 8(2). 1 indexed citations

Kinney, Anita Y., Scott T. Walters, Yong Lin, et al.. (2023). Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow. Journal of Clinical Oncology. 41(15). 2767–2778. 4 indexed citations

Crabtree, Benjamin F., Denalee O’Malley, Lisa Mikesell, et al.. (2023). Adapting and implementing breast cancer follow-up in primary care: protocol for a mixed methods hybrid type 1 effectiveness-implementation cluster randomized study. BMC Primary Care. 24(1). 235–235. 1 indexed citations

Kumar, Ritesh, Zeinab Abou Yehia, Shicha Kumar, et al.. (2023). Long-Term Clinical and Cosmetic Outcomes of Once-Daily Accelerated Partial Breast Irradiation in Early Breast Cancer. Advances in Radiation Oncology. 9(1). 101324–101324. 1 indexed citations

Zhang, Ziwei, Cristina I. Truica, Anne Blaes, et al.. (2022). Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.. Journal of Clinical Oncology. 40(16_suppl). e13014–e13014. 2 indexed citations

Matsuda, Kant, Gregory Riedlinger, Levi Sokol, et al.. (2021). Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. Case Reports in Oncology. 14(2). 931–937. 10 indexed citations

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2018). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology. 30(3). 405–411. 460 indexed citations breakdown →

Manne, Sharon L., et al.. (2018). Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy. Patient Education and Counseling. 102(5). 902–908. 10 indexed citations

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations

10.

Panda, Anshuman, Surendra Kumar, Michael Seiler, et al.. (2017). Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. Scientific Reports. 7(1). 5568–5568. 32 indexed citations

11.

Sharma, Manish, Elizabeth Gray, Kehua Wu, et al.. (2017). Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). The AAPS Journal. 19(5). 1411–1423. 6 indexed citations

12.

Toppmeyer, Deborah & Susan Goodin. (2010). Ixabepilone, a New Treatment Option for Metastatic Breast Cancer. American Journal of Clinical Oncology. 33(5). 516–521. 10 indexed citations

13.

Vázquez, Alexei, Diptee Kulkarni, John E. Kerrigan, et al.. (2010). Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Research and Treatment. 125(3). 861–868. 25 indexed citations

14.

Kelly, Kimberly M., Howard Leventhal, Monica Marvin, et al.. (2004). Subjective and Objective Risk of Breast Cancer in Ashkenazi Jewish Individuals at Risk for BRCA1/2 Mutations. Genetic Testing. 8(2). 139–147. 12 indexed citations

15.

Kelly, Kimberly M., Howard Leventhal, Monica Marvin, et al.. (2004). Subjective and Objective Risk of Breast Cancer in Ashkenazi Jewish Individuals at Risk for<I> BRCA1/2</I> Mutations. Genetic Testing. 8(2). 139–147.

16.

Kelly, Kimberly M., Howard Leventhal, Michael A. Andrykowski, et al.. (2004). Using the common sense model to understand perceived cancer risk in individuals testing for BRCA1/2 mutations. Psycho-Oncology. 14(1). 34–48. 66 indexed citations

17.

Villalona‐Calero, Miguel A., Sharyn D. Baker, L. A. Hammond, et al.. (1998). Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.. Journal of Clinical Oncology. 16(8). 2770–2779. 24 indexed citations

18.

Eder, Joseph P., Eric H. Rubin, Richard M. Stone, et al.. (1996). Trials of 9‐Amino‐20(S)‐Camptothecin in Boston. Annals of the New York Academy of Sciences. 803(1). 247–255. 9 indexed citations

19.

Toppmeyer, Deborah, Christopher A. Slapak, James M. Croop, & Donald Küfe. (1994). Role of P-glycoprotein in dolastatin 10 resistance. Biochemical Pharmacology. 48(3). 609–612. 30 indexed citations

20.

Lassman, Charles, et al.. (1992). Plasma cell-regulated polyadenylation at the Ig gamma 2b secretion-specific poly(A) site. The Journal of Immunology. 148(4). 1251–1260. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact